Skip to main content
Top
Published in: BMC Nephrology 1/2019

Open Access 01-12-2019 | Polycystic Kidney Disease | Research article

Revisiting racial differences in ESRD due to ADPKD in the United States

Authors: Erin L. Murphy, Feng Dai, Katrina Lehmann Blount, Madeline L. Droher, Lauren Liberti, Deidra C. Crews, Neera K. Dahl

Published in: BMC Nephrology | Issue 1/2019

Login to get access

Abstract

Introduction

Autosomal dominant polycystic kidney disease (ADPKD) affects all races. Whether the progression of ADPKD varies by race remains unclear.

Methods

In this retrospective cohort study from 2004 to 2013 non-Hispanic blacks and non-Hispanic whites of all ages classified in the US Renal Data System (USRDS) with incident ESRD from ADPKD (n = 23,647), hypertension/large vessel disease (n = 296,352), or diabetes mellitus (n = 451,760) were stratified into five-year age categories ranging from < 40 to > 75 (e.g., < 40, 40–44, 45–49, …, 75+). The Cochran-Mantel-Haenszel test was used to determine the association of race and incidence of ESRD from ADPKD, diabetes, or hypertension. The difference in the proportions of ESRD in non-Hispanic black and non-Hispanic white patients at each age categorical bin was compared by two-sample proportion test. The age of ESRD onset between non-Hispanic black and non-Hispanic white patients at each year was compared using two-sample t-test with unequal variance.

Results

1.068% of non-Hispanic blacks and 2.778% of non-Hispanic whites had ESRD attributed to ADPKD. Non-Hispanic blacks were less likely than non-Hispanic whites to have ESRD attributed to ADPKD (odds ratio (OR) (95% CI) = 0.38 (0.36–0.39), p <  0.0001). Using US Census data as the denominator to adjust for population differences non-Hispanic blacks were still slightly under-represented (OR (95% CI) 0.94 (0.91–0.96), p = 0.004). However, non-Hispanic blacks with ADPKD had a younger age of ESRD (54.4 years ±13) than non-Hispanic whites (55.9 years ±12.8) (p <  0.0001). For those < 40 years old, more non-Hispanic blacks had incident ESRD from ADPKD than non-Hispanic whites (9.49% vs. 7.68%, difference (95% CI) = 1.81% (0.87–2.84%), p <  0.001) for the combined years examined.

Conclusions

As previously shown, we find the incidence of ESRD from ADPKD in non-Hispanic blacks is lower than in non-Hispanic whites. Among the younger ADPKD population (age < 40), however, more non-Hispanic blacks initiated dialysis than non-Hispanic whites. Non-Hispanic blacks with ADPKD initiated dialysis younger than non-Hispanic whites. A potential implication of these findings may be that black race should be considered an additional risk factor for progression in ADPKD.
Literature
1.
go back to reference Levy M, Feingold J. Estimating prevalence in single-gene kidney diseases progressing to renal failure. Kidney Int. 2000;58(3):925–43.PubMedCrossRef Levy M, Feingold J. Estimating prevalence in single-gene kidney diseases progressing to renal failure. Kidney Int. 2000;58(3):925–43.PubMedCrossRef
2.
go back to reference Krishnappa V, Vinod P, Deverakonda D, Raina R. Autosomal dominant polycystic kidney disease and the heart and brain. Cleve Clin J Med. 2017;84(6):471–81.PubMedCrossRef Krishnappa V, Vinod P, Deverakonda D, Raina R. Autosomal dominant polycystic kidney disease and the heart and brain. Cleve Clin J Med. 2017;84(6):471–81.PubMedCrossRef
3.
go back to reference Chapman AB, Devuyst O, Eckardt KU, et al. Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a kidney disease: improving global outcomes (KDIGO) controversies conference. Kidney Int. 2015;88(1):17–27.PubMedPubMedCentralCrossRef Chapman AB, Devuyst O, Eckardt KU, et al. Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a kidney disease: improving global outcomes (KDIGO) controversies conference. Kidney Int. 2015;88(1):17–27.PubMedPubMedCentralCrossRef
4.
go back to reference Chapman AB, Guay-Woodford LM, Grantham JJ, et al. Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): the consortium for radiologic imaging studies of polycystic kidney disease (CRISP) cohort. Kidney Int. 2003;64(3):1035–45.PubMedCrossRef Chapman AB, Guay-Woodford LM, Grantham JJ, et al. Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): the consortium for radiologic imaging studies of polycystic kidney disease (CRISP) cohort. Kidney Int. 2003;64(3):1035–45.PubMedCrossRef
5.
go back to reference Torres VE, Chapman AB, Perrone RD, et al. Analysis of baseline parameters in the HALT polycystic kidney disease trials. Kidney Int. 2012;81(6):577–85.PubMedCrossRef Torres VE, Chapman AB, Perrone RD, et al. Analysis of baseline parameters in the HALT polycystic kidney disease trials. Kidney Int. 2012;81(6):577–85.PubMedCrossRef
6.
go back to reference Cornec-Le Gall E, Audrezet MP, Rousseau A, et al. The PROPKD score: a new algorithm to predict renal survival in autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 2016;27(3):942–51.PubMedCrossRef Cornec-Le Gall E, Audrezet MP, Rousseau A, et al. The PROPKD score: a new algorithm to predict renal survival in autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 2016;27(3):942–51.PubMedCrossRef
7.
go back to reference Cornec-Le Gall E, Blais JD, Irazabal MV, et al. Can we further enrich autosomal dominant polycystic kidney disease clinical trials for rapidly progressive patients? Application of the PROPKD score in the TEMPO trial. Nephrol Dialy Transplant. 2017;33(4):645–52.CrossRef Cornec-Le Gall E, Blais JD, Irazabal MV, et al. Can we further enrich autosomal dominant polycystic kidney disease clinical trials for rapidly progressive patients? Application of the PROPKD score in the TEMPO trial. Nephrol Dialy Transplant. 2017;33(4):645–52.CrossRef
8.
go back to reference Irazabal MV, Rangel LJ, Bergstralh EJ, et al. Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials. J Am Soc Nephrol. 2015;26(1):160–72.PubMedCrossRef Irazabal MV, Rangel LJ, Bergstralh EJ, et al. Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials. J Am Soc Nephrol. 2015;26(1):160–72.PubMedCrossRef
9.
go back to reference Yu ASLSC, Landsittel DP, Harris PC, Torres VE, Mrug M, et al. Baseline total kidney volume and the rate of kidney growth are associated with chronic kidney disease progression in autosomal dominant polycystic kidney disease. Kidney Int. 2018;93(3):691–9.PubMedCrossRef Yu ASLSC, Landsittel DP, Harris PC, Torres VE, Mrug M, et al. Baseline total kidney volume and the rate of kidney growth are associated with chronic kidney disease progression in autosomal dominant polycystic kidney disease. Kidney Int. 2018;93(3):691–9.PubMedCrossRef
10.
go back to reference Yium J, Gabow P, Johnson A, Kimberling W, Martinez-Maldonado M. Autosomal dominant polycystic kidney disease in blacks: clinical course and effects of sickle-cell hemoglobin. J Am Soc Nephrol. 1994;4(9):1670–4.PubMed Yium J, Gabow P, Johnson A, Kimberling W, Martinez-Maldonado M. Autosomal dominant polycystic kidney disease in blacks: clinical course and effects of sickle-cell hemoglobin. J Am Soc Nephrol. 1994;4(9):1670–4.PubMed
11.
go back to reference Abbott KC, Agodoa LY. Polycystic kidney disease at end-stage renal disease in the United States: patient characteristics and survival. Clin Nephrol. 2002;57(3):208–14.PubMedCrossRef Abbott KC, Agodoa LY. Polycystic kidney disease at end-stage renal disease in the United States: patient characteristics and survival. Clin Nephrol. 2002;57(3):208–14.PubMedCrossRef
12.
go back to reference Freedman BI, Soucie JM, Chapman A, Krishner J, McClellan WM. Racial variation in autosomal dominant polycystic kidney disease. Am J Kidney Dis. 2000;35(1):35–9.PubMedCrossRef Freedman BI, Soucie JM, Chapman A, Krishner J, McClellan WM. Racial variation in autosomal dominant polycystic kidney disease. Am J Kidney Dis. 2000;35(1):35–9.PubMedCrossRef
13.
go back to reference Reule S, Sexton DJ, Solid CA, Chen SC, Collins AJ, Foley RN. ESRD from autosomal dominant polycystic kidney disease in the United States, 2001-2010. Am J Kidney Dis. 2014;64(4):592–9.PubMedPubMedCentralCrossRef Reule S, Sexton DJ, Solid CA, Chen SC, Collins AJ, Foley RN. ESRD from autosomal dominant polycystic kidney disease in the United States, 2001-2010. Am J Kidney Dis. 2014;64(4):592–9.PubMedPubMedCentralCrossRef
15.
go back to reference Age-adjusted prevalence of CKD Stages 1–4 by Race/Ethnicity 2013–2014. Chronic Kidney Disease (CKD) Surveillance Project System. Centers for Disease Control and Prevention https://nccd.cdc.gov/CKD/. Age-adjusted prevalence of CKD Stages 1–4 by Race/Ethnicity 2013–2014. Chronic Kidney Disease (CKD) Surveillance Project System. Centers for Disease Control and Prevention https://​nccd.​cdc.​gov/​CKD/​.
16.
go back to reference Hsu CY, Lin F, Vittinghoff E, Shlipak MG. Racial differences in the progression from chronic renal insufficiency to end-stage renal disease in the United States. J Am Soc Nephrol. 2003;14(11):2902–7.PubMedCrossRef Hsu CY, Lin F, Vittinghoff E, Shlipak MG. Racial differences in the progression from chronic renal insufficiency to end-stage renal disease in the United States. J Am Soc Nephrol. 2003;14(11):2902–7.PubMedCrossRef
17.
go back to reference Evans K, Coresh J, Bash LD, et al. Race differences in access to health care and disparities in incident chronic kidney disease in the US. Nephrol Dial Transplant. 2011;26(3):899–908.PubMedCrossRef Evans K, Coresh J, Bash LD, et al. Race differences in access to health care and disparities in incident chronic kidney disease in the US. Nephrol Dial Transplant. 2011;26(3):899–908.PubMedCrossRef
18.
go back to reference Green JA, Mor MK, Shields AM, et al. Associations of health literacy with dialysis adherence and health resource utilization in patients receiving maintenance hemodialysis. Am J Kidney Dis. 2013;62(1):73–80.PubMedCrossRef Green JA, Mor MK, Shields AM, et al. Associations of health literacy with dialysis adherence and health resource utilization in patients receiving maintenance hemodialysis. Am J Kidney Dis. 2013;62(1):73–80.PubMedCrossRef
19.
go back to reference Ayanian JZ, Cleary PD, Keogh JH, Noonan SJ, David-Kasdan JA, Epstein AM. Physicians' beliefs about racial differences in referral for renal transplantation. Am J Kidney Dis. 2004;43(2):350–7.PubMedCrossRef Ayanian JZ, Cleary PD, Keogh JH, Noonan SJ, David-Kasdan JA, Epstein AM. Physicians' beliefs about racial differences in referral for renal transplantation. Am J Kidney Dis. 2004;43(2):350–7.PubMedCrossRef
20.
go back to reference Rodriguez RA, Sen S, Mehta K, Moody-Ayers S, Bacchetti P, O'Hare AM. Geography matters: relationships among urban residential segregation, dialysis facilities, and patient outcomes. Ann Intern Med. 2007;146(7):493–501.PubMedCrossRef Rodriguez RA, Sen S, Mehta K, Moody-Ayers S, Bacchetti P, O'Hare AM. Geography matters: relationships among urban residential segregation, dialysis facilities, and patient outcomes. Ann Intern Med. 2007;146(7):493–501.PubMedCrossRef
21.
go back to reference Crews DC, Pfaff T, Powe NR. Socioeconomic factors and racial disparities in kidney disease outcomes. Semin Nephrol. 2013;33(5):468–75.PubMedCrossRef Crews DC, Pfaff T, Powe NR. Socioeconomic factors and racial disparities in kidney disease outcomes. Semin Nephrol. 2013;33(5):468–75.PubMedCrossRef
22.
23.
go back to reference Limou S, Nelson GW, Kopp JB, Winkler CA. APOL1 kidney risk alleles: population genetics and disease associations. Adv Chronic Kidney Dis. 2014;21(5):426–33.PubMedPubMedCentralCrossRef Limou S, Nelson GW, Kopp JB, Winkler CA. APOL1 kidney risk alleles: population genetics and disease associations. Adv Chronic Kidney Dis. 2014;21(5):426–33.PubMedPubMedCentralCrossRef
24.
go back to reference Parsa AKL, Xie D, Astor BC, Li M, Hsu C, et al. APOL1 risk Varients, race, and progression of chronic kidney disease. N Engl J Med. 2014;369(23):2183–96.CrossRef Parsa AKL, Xie D, Astor BC, Li M, Hsu C, et al. APOL1 risk Varients, race, and progression of chronic kidney disease. N Engl J Med. 2014;369(23):2183–96.CrossRef
Metadata
Title
Revisiting racial differences in ESRD due to ADPKD in the United States
Authors
Erin L. Murphy
Feng Dai
Katrina Lehmann Blount
Madeline L. Droher
Lauren Liberti
Deidra C. Crews
Neera K. Dahl
Publication date
01-12-2019
Publisher
BioMed Central
Published in
BMC Nephrology / Issue 1/2019
Electronic ISSN: 1471-2369
DOI
https://doi.org/10.1186/s12882-019-1241-1

Other articles of this Issue 1/2019

BMC Nephrology 1/2019 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.